title: Thrombotic thrombocytopenic purpura: early and late responders.
abstract: Thrombotic thrombocytopenic purpura (TTP) is characterized by micro-angiopathic hemolytic anemia (MAHA), thrombocytopenia, neurological symptoms, renal involvement, and fever. We describe our experience in 70 serially encountered TTP patients in the last decade who were treated with a standard therapeutic plasma exchange (TPE) protocol. Seventy percent of the patients were females. The median age of the patients was 43 years (range: 8-80). Sixty patients (85.7%) had a complete response to TPE therapy. This represented 91% of 66 who received at least one TPE. Ten patients died, two patients died before and two during the first plasma exchange. The median number of TPEs performed was nine (range: 1-85). Thirty-five (58%) out of 60 responded to 3-9 TPEs, and 25 (42%) required 10-34 TPEs for the response. The median total plasma volume exchanged was 28 liters (range: 2.7-250 L) and the mean plasma volumes exchanged during each procedure was 3.2 (SD +/- 1.09 L). The patients were classified into early responders (ER) and late responders (LR). ERs had a mean platelet count of 180 x 10(9)/L by Day 5, mean LDH of 643 IU/L by Day 7, and required median of seven TPEs. LRs had a mean platelet count of 122 x 10(9)/L by Day 5, mean LDH of 885 IU/L by Day 7, and required median of 19 TPEs (P = 0.001). The platelet counts were significantly higher (P = 0.01-0.03) in ERs on Days 1, 3, and 5 as compared to LRs but the LDH did not differ significantly. Seventy-seven percent of LRs had exacerbation of TTP and 18% had relapse as compared to 7% each in ERs. Thirteen patients were in coma/semicoma at presentation. Out of these, six died, making coma a bad prognostic indicator. Five of the seven survivors in coma had received two single-plasma volume exchanges on Day 1. In conclusion, 91% of TTP patients had an excellent response to plasma exchange therapy with FFR Coma/ semicoma appears to be a bad prognostic indicator. LRs needed prolonged treatment with a greater number of patients experiencing exacerbation and relapse of TTP as compared to ERs.
authors.affiliation: The Blood Center of Southeastern Wisconsin, Inc., Milwaukee 53201, USA.
authors.forename: R
authors.initials: R
authors.lastname: Sarode
authors.forename: J L
authors.initials: JL
authors.lastname: Gottschall
authors.forename: R H
authors.initials: RH
authors.lastname: Aster
authors.forename: J G
authors.initials: JG
authors.lastname: McFarland
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003128:Coma / Q000209:etiology; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange / Q000009:adverse effects; D011697:Purpura, Thrombotic Thrombocytopenic / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D065227:Transfusion Reaction; D016896:Treatment Outcome